The advent of optogenetics, chemogenetics, and high-density neural recording technologies has propelled systems neuroscience into a golden age, generating unprecedented mechanistic insights into how defined neural circuits orchestrate behaviour. These tools have allowed us to move beyond correlational observations to establish causal links between specific circuit dynamics and behavioural states. However, a profound and disheartening translational dilemma has emerged: the pace at which these foundational discoveries in model organisms have yielded novel, effective therapeutics for human neuropsychiatric disorders remains glacial. This review argues that this dilemma is not a failure of the science itself but a consequence of a multi-layered gulf between basic discovery and clinical application. This gulf encompasses technological, phenomenological, and biological disparities. We analyse the roots of this impasse and propose a concerted, multi-pronged strategy to bridge it, focusing on back-translation, cross-species behavioural dimensionalization, the development of non-invasive neuromodulation, and the fostering of deeply integrated interdisciplinary collaborations. The path forward requires a fundamental shift in how we design, interpret, and prioritize neural circuit research with translation in mind.
Wang et al. (Fri,) studied this question.